SCHEMBL971264

SCHEMBL971264

Cc1ccc(S(=O)(=O)ON2CCC(c3cccc(CNC(=O)OC(C)(C)C)c3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.43
USP5 P45974 3/20 0.41
ALOX12 P18054 1/20 0.40
PKM P14618 1/20 0.40
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
DRD2 P14416 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
DRD5 P21918 1/20 0.38
DRD3 P35462 1/20 0.38
BRD4 O60885 2/20 0.38
P2RX7 Q99572 2/20 0.38
HPN P05981 1/20 0.38
HGFAC Q04756 1/20 0.38
ST14 Q9Y5Y6 1/20 0.38
CREBBP Q92793 1/20 0.38
CA1 P00915 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971262 0.83 TRPA1 (0.41) TRPA1USP5ALOX12PKMTP53
SCHEMBL973927 0.81 BRD4 (0.42) TRPA1TP53BRD4CREBBP
SCHEMBL30531024 0.80 BRD4 (0.48) TRPA1BRD4CREBBPCA1
SCHEMBL3509882 0.80 BRD4 (0.48) TRPA1BRD4CREBBPCA1
SCHEMBL13830591 0.79 QDPR (0.45) TP53BRD4CREBBP
SCHEMBL25048390 0.78 BRD4 (0.47) TRPA1BRD4CREBBP
SCHEMBL30531063 0.78 GLS (0.48) TRPA1BRD4CREBBP
SCHEMBL25358558 0.78 GLS (0.48) TRPA1BRD4CREBBP
SCHEMBL27679079 0.77 CHRM4 (0.43) DRD2DRD4DRD3BRD4CREBBP
SCHEMBL19387643 0.76 TEAD1 (0.46) TP53BRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130225825-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-08-29 US disclosed
US-20110015400-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-01-20 US disclosed
EP-1723140-B1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMA INC (US) 2009-11-04 EP disclosed
US-20070197597-A1 Process for the preparation of tryptase inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed
EP-1723140-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS Aventis Pharmaceuticals Inc. (US) 2006-11-22 EP disclosed
WO-2005095385-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2005-10-13 WO disclosed
EP-1571150-A1 Process for the preparation of tryptase inhibitors Aventis Pharma Deutschland GmbH (DE) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225825-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS CMA1, TPSAB1, TPSB2 TRPA1 1131/4885USP5 1817/4885ALOX12 946/4885
US-20110015400-A1 PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS CMA1, TPSAB1, TPSB2 TRPA1 1131/4885USP5 1817/4885ALOX12 946/4885
US-20070197597-A1 Process for the preparation of tryptase inhibitors CMA1, TPSAB1, TPSB2 TRPA1 1131/4885USP5 1817/4885ALOX12 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.